Fluid-based biomarkers are increasingly critical for predicting therapeutic response and adverse events in immuno-oncology, where patient heterogeneity drives variable outcomes. Traditional tissue biopsies are limited by invasiveness and sampling bias, highlighting the need for scalable, noninvasive approaches. Genetic assays provide information about the tumor burden but not about the immune response. NULISA Technology overcomes these challenges through ultra-sensitive, multiplexed protein detection from small volumes of blood, enabling robust quantification of low-abundance biomarkers across a wide dynamic range. This capability supports longitudinal monitoring of immune activity, early identification of responders and non-responders, and detection of toxicity signals. By providing precise, reproducible measurements, NULISA empowers more informed clinical decisions, enhances trial design, and advances personalized immunotherapy strategies.
CSO
Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.
CFO
Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.